Clinical trials: Botulinum Toxin
Depressive Disorder, Major
OnabotulinumtoxinA as Treatment for Major Depressive Disorder in Adult Females
This study will evaluate the safety and efficacy of onabotulinumtoxinA (BOTOX®) compared with placebo as treatment for major depressive disorder (MDD) in adult females.
- Trial name
- NCT02116361
- Testing
- onabotulinumtoxinA, Normal Saline
- Where
- 35 sites in United States
- Volunteers
- 258 people
- Sponsor
- Allergan
Essential Tremor of the Upper Limbs
Botulinum Toxin A to Treat Arm Tremor
The objective of this study is to assess the efficacy and safety of a single, kinematic-analysis-based intramuscular injection of NT 201, compared with placebo, in moderate to marked essential tremor of the upper limb.
- Trial name
- NCT02207946
- Testing
- IncobotulinumtoxinA
- Where
- 6 sites in United States, Canada
- Volunteers
- 30 people
- Sponsor
- Merz Pharmaceuticals GmbH
Botulism
BT-010 Registry for the Evaluation of Safety and Clinical Outcomes in Patients Treated With Botulinum Antitoxin
The purpose of the Registry was to evaluate patient safety following Botulism Antitoxin Heptavalent (A, B, C, D, E, F, G) - (Equine) (BAT®) administration in adult and pediatric patients with a confirmed or suspected exposure to…
- Trial name
- NCT02055183
- Testing
- BAT
- Volunteers
- 162 people
- Sponsor
- Emergent BioSolutions
Moderate to Severe Glabellar Lines
A Study to Investigate the Safety and Efficacy of YY003 in Adults With Moderate to Severe Glabellar Lines
The study is a two-part (Part A and Part B) randomized double-blind vehicle-controlled multi-center study in a total of 174 participants with moderate to severe glabellar lines.
- Trial name
- NCT06481475
- Testing
- YY003, Vehicle Control
- Where
- 3 sites in Australia
- Volunteers
- 153 people
- Sponsor
- Chongqing Claruvis Pharmaceutical Co., Ltd.
Glabellar Frown Lines
Study to Compare the Efficacy and Safety of ATGC-110 (Botulinum Toxin) With Xeomin® for the Treatment of Moderate to Severe Glabellar Frown Lines
Efficacy and safety of the investigational product, ATGC-110, was evaluated in comparison with Xeomin for a total of 16 weeks after the administration in treatment of glabellar frown lines.
- Trial name
- NCT05623410
- Testing
- ATGC-110, Xeomin®
- Where
- South Korea
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- ATGC Co., Ltd.
Episodic Migraine
Study of BOTOX Injections in Prevention of Migraine in Adult Participants With Episodic Migraine
Migraine is a neurological disease characterized by moderate or severe headache, associated with nausea, vomiting, and/or sensitivity to light and sound (International Classification of Headache Disorders, 2018).
- Trial name
- NCT05028569
- Testing
- BOTOX
- Where
- 133 sites in United States, Canada and 7 more
- Volunteers
- 775 people
- Sponsor
- AbbVie
Spasmodic Torticollis
Comparison of Efficacy and Safety of Two Different Types of Botulinum Toxin Type A in Moderate to Severe Cervical Dystonia
The purpose of this study is to compare two types of botulinum toxin type A to treat the involuntary muscle contractions in the neck
- Trial name
- NCT00528541
- Testing
- botulinum toxin type A
- Where
- 5 sites in Australia, Croatia and 3 more
- Volunteers
- 145 people
- Sponsor
- Allergan
Moderate to Severe Glabellar Lines
DWP450 for Treating Moderate to Severe Glabellar Lines
A multi-center, randomized, double-blind, positive drug-controlled clinical study to evaluate the safety and efficacy of Botulinum Toxin Type A for Injection in the treatment of moderate to severe glabellar lines
- Trial name
- NCT06354127
- Testing
- DWP450, Botox®
- Where
- China
- Volunteers
- 473 people
- Sponsor
- Daewoong Pharmaceutical Co. LTD.
Glabellar Frown Lines
Botulinum Toxin Treatment of Glabellar Lines: Efficacy and Safety Study III (BLESSIII)
The aim of this study is to assess the efficacy and safety of BoNT/A-DP in the treatment of glabellar lines in comparison with placebo, including efficacy after repeat treatments and long term safety.
- Trial name
- BLESSIII (NCT03985982)
- Testing
- Botulinum Toxin A
- Where
- United States
- Volunteers
- 410 people
- Sponsor
- Croma-Pharma GmbH
Urinary Bladder, Overactive
Efficacy and Safety of GSK1358820 in Subjects With Overactive Bladder
GSK1358820 is a botulinum neurotoxin A complex that has been approved for the treatment of overactive bladder (OAB) in several countries, however, it has not been approved for OAB treatment in Japan.
- Trial name
- NCT02820844
- Testing
- GSK1358820, Antibiotic therapy, Bladder diary
- Where
- 48 sites in Japan
- Volunteers
- 250 people
- Sponsor
- GlaxoSmithKline
Lateral Canthal Lines
Safety and Efficacy Study of RT001 to Treat Moderate to Severe Lateral Canthal Lines
The purpose of this study is to determine the safety and efficacy of 2 sequential doses of RT001 compared to vehicle control following applications at Baseline (Day 0) and Week 2.
- Trial name
- NCT00884234
- Testing
- Vehicle Control, RT001 (Botulinum Toxin Type A Topical Gel)
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Revance Therapeutics, Inc.
Overactive Bladder
Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Neurogenic Overactive Bladder
This study will assess the safety and efficacy of botulinum toxin Type A for the treatment of urinary incontinence overactive bladder in patients with a spinal cord injury or multiple sclerosis.
- Trial name
- NCT00439140
- Testing
- botulinum toxin Type A
- Where
- 4 sites in United States, Australia and 2 more
- Volunteers
- 41 people
- Sponsor
- Allergan
Glabellar Lines
Phase 2 of HU-045 in Glabellar Lines
A Multicenter, Double-blind, Randomized, Parallel, Active-controlled, Phase II Clinical Trial to Evaluate the Efficacy and Safety of HU-045 and Xeomin® in Patients With Moderate to Severe Glabellar Lines
- Trial name
- NCT05298449
- Testing
- HU-045, Xeomin®
- Where
- South Korea
- Volunteers
- 50 people
- Sponsor
- Huons Co., Ltd.
Urinary Bladder, Overactive
Efficacy and Safety Study of GSK1358820 in Japanese Patients With Urinary Incontinence Due to Neurogenic Detrusor Overactivity
This study will evaluate the efficacy and safety of GSK1358820 in Japanese patients with neurogenic detrusor overactivity (NDO) with urinary incontinence, whose symptoms have not been adequately managed with medications for…
- Trial name
- NCT02849418
- Testing
- GSK1358820
- Where
- 9 sites in Japan
- Volunteers
- 21 people
- Sponsor
- GlaxoSmithKline
Glabellar Rhytides, Frown Lines Between the Eyebrows
Safety and Efficacy Study of Repeat Treatment With PurTox® Botulinum Toxin Type A for Frown Lines Between the Eyebrows
The overall purpose of this study is to evaluate the safety and effectiveness of repeat treatment of an intramuscular dose of Mentor Purified Toxin for the reduction of frown lines, compared with placebo.
- Trial name
- PT-03b (NCT00752050)
- Testing
- Mentor Purified Toxin Botulinum Toxin Type A, Preservative-free Saline
- Where
- United States
- Volunteers
- 699 people
- Sponsor
- Mentor Worldwide, LLC
Cervical Dystonia
Study to Assess the Efficacy and Safety of Dysport® in Cervical Dystonia
The aim is to demonstrate equivalent efficacy and safety in the treatment of the two most frequent forms of cervical dystonia (predominantly rotational torticollis and predominantly laterocollis) with the standard initial dose of…
- Trial name
- NCT00447772
- Testing
- Botulinum toxin type A
- Where
- 106 sites in Austria, Germany
- Volunteers
- 516 people
- Sponsor
- Ipsen
Upper Limb Spasticity
A Study on Recombinant Botulinum Toxin Type A (YY001) for Injection in Multiple Treatments of Adult Upper Limb Spasticity
This is an open-label, multicenter, phase III clinical study to evaluate the long-term safety and efficacy of multiple treatments with recombinant botulinum toxin type A (YY001) for injection in adult upper limb spasticity
- Trial name
- NCT07478822
- Testing
- Recombinant botulinum toxin type A for injection (YY001)
- Where
- 16 sites in China
- Volunteers
- 300 people
- Sponsor
- Chongqing Claruvis Pharmaceutical Co., Ltd.
Upper Limb Spasticity After Stroke
A Prospective, Non-interventional Survey to Evaluate Injection Intervals and Treatment Modalities of Botulinum Toxin A (BoNT-A) in Adult Patients Suffering From Upper Limb Spasticity After Stroke
The purpose of the protocol is to evaluate injection intervals and treatment modalities up to 3 years follow-up of botulinum toxin A (BoNT-A) in adult patients suffering from upper limb spasticity after stroke.
- Trial name
- DECIDE (NCT01239628)
- Where
- 11 sites in Belgium
- Volunteers
- 45 people
- Sponsor
- Ipsen
Cervical Dystonia
Post-marketing Surveillance of Administration of Botulinum Toxin Type B(NerBloc)-Investigation of the Clinical Condition in Patients With Change From Botulinum Toxin Type A
Investigation of the clinical condition in patients with cervical dystonia by Toronto Western Spasmodic Torticollis Scale (TWSTRS)
- Trial name
- NCT02175719
- Where
- 2 sites in Japan
- Volunteers
- 150 people
- Sponsor
- Eisai Co., Ltd.
Cervical Dystonia
Open Label Safety/Immunogenicity Study of MYOBLOC (Neurobloc; Botulinum Toxin Type B) in Patients With Cervical Dystonia
Open label study to evaluate the safety and immunogenicity of MYOBLOC (Botulinum Toxin Type B) in adult patients with a clinical diagnosis of Cervical Dystonia (CD).
- Trial name
- NCT00702754
- Testing
- Botulinum Toxin Type B
- Volunteers
- 502 people
- Sponsor
- Solstice Neurosciences, LLC, a subsidiary of US WorldMeds, LLC